Fetal protection following exposure to calves persistently infected with bovine viral diarrhea virus type 2 sixteen months after primary vaccination of the dams.
This study demonstrated that the bovine viral diarrhea virus (BVDV; types 1 and 2) fractions of a multivalent vaccine protected pregnant heifers and their fetuses at 149 to 217 days of gestation against exposure to calves persistently infected with BVDV type 2a. Eighty percent (eight of 10) of the control heifers were viremic at least 1 day following challenge, whereas all (20 of 20) BVDV-vaccinated heifers were virus isolation-negative on all postchallenge assessment days. Ninety percent (nine of 10) of the calves born to control heifers but only 5% (one of 20) of calves born to BVDV-vaccinated heifers seroconverted to BVDV type 2 before ingesting colostrum. One calf born to a control heifer was persistently infected. No calves from BVDV-vaccinated heifers were persistently infected.
Ellsworth
Michael A
MA
Pfizer Global Manufacturing, 601 West Cornhusker Highway, Lincoln, Nebraska 68521, USA.
Fairbanks
Kris K
KK
Behan
Stephen
S
Jackson
James A
JA
Goodyear
Mark
M
Oien
Nancee L
NL
Meinert
Todd R
TR
Leyh
Randy D
RD
D000818:Animals; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000517:prevention & control* / Q000635:transmission; D002417:Cattle; D030242:Diarrhea Virus 2, Bovine Viral / Q000276:immunology*; D005260:Female; D005315:Fetal Diseases / Q000517:prevention & control / Q000662:veterinary / Q000821:virology; D009500:Neutralization Tests / Q000662:veterinary; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control / Q000662:veterinary*; D011270:Pregnancy, Animal / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary*; D017778:Vaccines, Combined; D014765:Viral Vaccines
D017778:Vaccines, Combined; D014765:Viral Vaccines